Folgen
de Visser Karin. E
de Visser Karin. E
Professor at the LUMC, group leader at the Netherlands Cancer Institute and Oncode Institute
Bestätigte E-Mail-Adresse bei nki.nl - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Paradoxical roles of the immune system during cancer development
KE De Visser, A Eichten, LM Coussens
Nature reviews cancer 6 (1), 24-37, 2006
29422006
IL-17-producing gdT cells and neutrophils conspire to promote breast cancer metastasis
SB Coffelt, K Kersten, CW Doornebal, J Weiden, K Vrijland, CS Hau, ...
Nature, 2015
17282015
Neutrophils in cancer: neutral no more
SB Coffelt, MD Wellenstein, KE de Visser
Nature Reviews Cancer 16 (7), 431-446, 2016
16932016
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy
CH Ries, MA Cannarile, S Hoves, J Benz, K Wartha, V Runza, ...
Cancer cell 25 (6), 846-859, 2014
13862014
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
KE de Visser, JA Joyce
Cancer Cell 41 (3), 374-403, 2023
11412023
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
KE de Visser, LV Korets, LM Coussens
Cancer cell 7 (5), 411-423, 2005
9842005
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ...
Nature medicine 25 (6), 920-928, 2019
7862019
FcRγ activation regulates inflammation-associated squamous carcinogenesis
P Andreu, M Johansson, NI Affara, F Pucci, T Tan, S Junankar, L Korets, ...
Cancer cell 17 (2), 121-134, 2010
6422010
Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape
MD Wellenstein, KE de Visser
Immunity 48 (3), 399-416, 2018
5922018
Genetically engineered mouse models in oncology research and cancer medicine
K Kersten, KE de Visser, MH van Miltenburg, J Jonkers
EMBO molecular medicine 9 (2), 137-153, 2017
5122017
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
HL Greenstone, JD Nieland, KE De Visser, MLH De Bruijn, R Kirnbauer, ...
Proceedings of the National Academy of Sciences 95 (4), 1800-1805, 1998
4651998
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
MD Wellenstein, SB Coffelt, DEM Duits, MH van Miltenburg, M Slagter, ...
Nature 572 (7770), 538-542, 2019
4362019
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
S Rottenberg, AOH Nygren, M Pajic, FWB van Leeuwen, ...
Proceedings of the National Academy of Sciences 104 (29), 12117-12122, 2007
3692007
Immune crosstalk in cancer progression and metastatic spread: a complex conversation
H Garner, KE de Visser
Nature Reviews Immunology 20 (8), 483-497, 2020
3632020
The inflammatory tumor microenvironment and its impact on cancer development
K de Visser, L Coussens
Infection and Inflammation: Impacts on Oncogenesis 13, 118-137, 2006
2992006
Inflammation, proteases and cancer
LCL van Kempen, KE de Visser, LM Coussens
European journal of cancer 42 (6), 728-734, 2006
2382006
Effects of TGF-β on the immune system: implications for cancer immunotherapy
KE De Visser, WM Kast
Leukemia 13 (8), 1188-1199, 1999
2341999
Neutrophil phenotypes and functions in cancer: A consensus statement
DF Quail, B Amulic, M Aziz, BJ Barnes, E Eruslanov, ZG Fridlender, ...
Journal of Experimental Medicine 219 (6), e20220011, 2022
2092022
Developmental stage‐specific contribution of LGR5+ cells to basal and luminal epithelial lineages in the postnatal mammary gland
KE de Visser, M Ciampricotti, E Michalak, D Wei‐Min Tan, EN Speksnijder, ...
The Journal of Pathology, 2012
2022012
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
C Salvagno, M Ciampricotti, S Tuit, CS Hau, A van Weverwijk, SB Coffelt, ...
Nature cell biology 21 (4), 511-521, 2019
1672019
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20